NCT01375179View on ClinicalTrials.gov

Efficacy & Safety in Moderately Active Refractory Ulcerative Colitis Patients

PHASE2TerminatedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Ulcerative Colitis
Interventions
DRUG

KRP203

DRUG

Placebo matching KRP203

Trial Locations (14)

1083

Novartis Investigative Site, Budapest

3000

Novartis Investigative Site, Leuven

3010

Novartis Investigative Site, Bern

4032

Novartis Investigative Site, Debrecen

8091

Novartis Investigative Site, Zurich

9000

Novartis Investigative Site, Ghent

20148

Novartis Investigative Site, Hamburg

51103

Novartis Investigative Site, Cologne

60318

Novartis Investigative Site, Frankfurt am Main

116 91

Novartis Investigative Site, Stockholm

SE-141 86

Novartis Investigative Site, Stockholm

751 85

Novartis Investigative Site, Uppsala

OX3 9DU

Novartis Investigative Site, Oxford

NG7 2UH

Novartis Investigative Site, Nottingham

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY